Following the success of this year’s Awards, with feedback indicating it brought something new and inclusive to the ecosystem, One Nucleus is delighted to announce our Annual Awards 2025.
The continued success of the Life Sciences sector is built on the excellence of all its stakeholders hence One Nucleus feels we should celebrate by recognising all parts of our community including life science innovators, R&D companies, non-profit organisations, technical providers and professional advisors.
Recognition of everyone’s valuable contribution to improving patient outcomes is reflected in the…
Our Strategic Partnership with RESI London: What It Means For YouGenesis has been an anchor event for debate and knowledge-sharing about the developments and trends in our sector for many years. From its small beginnings as a ‘London Biotechnology Network Showcase’, it has evolved with the sector to remain central to our ecosystem, taking stock of achievements, challenges, and visions as we near the end of each year.
Accessing capital remains very tough everywhere, and early-stage companies are feeling the heat as much as anyone. There are positive signs with some high value and striking…
Funding from Anglia Ruskin University is helping small firms' cutting-edge initiatives
Virtual reality therapy for people suffering from mental health disorders, using AI to manage demand on NHS services, and technology that listens to a child’s cough to assist early diagnoses are among the Essex innovations that have received thousands of pounds of funding from Arise Innovation Hubs – part of Anglia Ruskin University (ARU).
The ABOVE (Arise Beyond Open Innovation for Value and Entrepreneurship) innovation support grants are aimed at assisting small and medium-sized…
Funds raised to continue advanced pre-clinical trials of novel gene therapies to treat blindness and major chronic eye disease
Led by LifeArc Ventures and Parkwalk Advisors, with participation from the UK Innovation, Science and Seed Fund, managed by Future Planet Capital (UKI2S)
Dr Jean-Philippe Combal of Vivet Therapeutics and SpliceBio appointed as NED
Norwich, UK, October 23 2024 – Ikarovec, which is developing novel bicistronic gene therapies for major chronic eye diseases, is pleased to announce that it has extended its seed funding round by £5M, bringing the total raised to £8M…
Sandwich, Kent, UK / 23 October 2024 / In a bid to enable future success and growth, ten entrepreneurial life science and technology businesses have begun the immersive Discovery Spark programme, with a prize package worth over £50,000 up for grabs.
Based in Sandwich, Kent, Discovery Park is a leading science and innovation campus offering a range of impressive facilities for dynamic start-ups through to global corporations. Now in its third iteration, the Discovery Spark programme equips early stage life science and technology businesses with the skills and tools to lay healthy…
Digital pathology is used within pathology, computer science and image analysis and is transforming how pathologists diagnose and research diseases. Within this article, we will conduct a deep dive into the benefits of digital pathology. While doing this, we will emphasise its impact on healthcare outcomes, research and education.
Read article here:
https://sourcebioscience.com/what-are-the-benefits-of-digital-pathology/
Stevenage, UK, 22 October 2024 - Laverock Therapeutics, a gene-silencing company with a uniquely powerful technology for the development of programmable advanced therapies to tackle major diseases, today announces it is to present new data on its innovative gene-silencing platform at the European Society of Gene & Cell Therapy (ESGCT) Conference in Rome 22-25 October.
Led by COO Tom Payne, Laverock’s team of scientists will be presenting three posters covering the Company’s technology platform and its application to CAR T cells and tumour microenvironment (TME) responsive macrophages for…
CPI has fully opened its RNA Centre of Excellence to support the rising demand for RNA-based therapies and vaccines. The service offers comprehensive support, including plasmid DNA production, RNA transcription, purification, and formulation, alongside process development, analytics, and regulatory guidance.
Located at CPI’s National Biologics Manufacturing Centre in Darlington, the RNA Centre helps companies at all stages, from research to clinical trials, scale up RNA production. The GMP facility has been set up to enable industry to take projects from DNA to…
tranScrip is delighted to announce the appointment of Roz Sutton as Senior Director of Regulatory Affairs. Roz brings two decades of experience in Global Regulatory Affairs, having held leadership roles at top pharmaceutical companies including Roche and GSK, as well as in regulatory consultancy at DLRC. Her appointment underscores tranScrip’s commitment to strengthening its regulatory team as it continues to expand its expertise and service offerings.
A highly experienced regulatory strategist, Roz has led regulatory initiatives across key therapeutic areas such as ophthalmology,…
We are delighted to announce that Dr. Kathryn (Kate) Owen has joined tranScrip as Executive Medical Director in our Early Development Group.
Kate brings with her 24 years of extensive experience as a consultant Pharmaceutical Physician, with a specialised focus in oncology and haemato-oncology. She has an exceptional track record in early clinical development, guiding projects from candidate drug selection through to phase IIb trials.
Throughout her 16-year career at AstraZeneca, Kate held various pivotal roles in early development, before transitioning into consultancy. For the past 8 years…